We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+2.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$833M
AUM Growth
-$400M
(-32%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-28.81%
Top 10 Holdings %
Top 10 Hldgs %
56.65%
Holding
156
New
48
Increased
29
Reduced
27
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$25M |
| 2 |
CELG
Celgene Corp
CELG
|
+$22.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$21.2M |
| 4 |
MacroGenics
MGNX
|
+$18.8M |
| 5 |
MannKind Corp
MNKD
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$144M |
| 2 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$69.5M |
| 3 |
Gilead Sciences
GILD
|
+$56.7M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$26.6M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.14% |
| 2 | Miscellaneous | 12.73% |
| 3 | Consumer Staples | 2.06% |
| 4 | Consumer Discretionary | 0.05% |
| 5 | Industrials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XNPT
76
DELISTED
XENOPORT, INC.
XNPT
| $288K | 0.03% |
50,000
+1,750
| +4% | +$9.47K |
|
|
CUTR
77
DELISTED
Cutera, Inc.
CUTR
| $228K | 0.03% |
22,400
+10,000
| +81% | +$94K |
|
|
LCI
78
DELISTED
Lannett Company, Inc.
LCI
| $223K | 0.03% |
+1,686
| New | +$178K |
|
79
Illumina
ILMN
$33.6B
| $221K | 0.03% |
+2,056
| New | +$188K |
|
|
INSY
80
DELISTED
Insys Therapeutics, Inc.
INSY
| $221K | 0.03% |
+17,166
| New | +$238K |
|
|
MDSO
81
DELISTED
Medidata Solutions, Inc.
MDSO
| $220K | 0.03% |
+3,642
| New | +$202K |
|
82
PUT
Myriad Genetics
MYGN
$371M
| $210K | 0.03% |
+10,000
| New | +$253K |
|
|
NAVB
83
PUT
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $207K | 0.02% |
5,000
-825
| -14% | -$32.3K |
|
|
TRNX
84
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $188K | 0.02% |
+10,000
| New | +$189K |
|
|
FLNA
85
Filana Therapeutics
FLNA
$33.6M
| $172K | 0.02% |
+5,072
| New | +$135K |
|
86
Centene
CNC
$33.4B
| $154K | 0.02% |
10,440
+1,020
| +11% | +$15.3K |
|
87
AstraZeneca
AZN
$251B
| $152K | 0.02% |
2,558
-142
| -5% | -$7.71K |
|
|
HRC
88
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $152K | 0.02% |
+3,687
| New | +$148K |
|
89
DaVita
DVA
$12.2B
| $151K | 0.02% |
2,382
+72
| +3% | +$4.22K |
|
|
IPXL
90
DELISTED
Impax Laboratories, Inc.
IPXL
| $150K | 0.02% |
+5,962
| New | +$133K |
|
|
OCR
91
DELISTED
OMNICARE INC
OCR
| $150K | 0.02% |
2,492
-33
| -1% | -$1.89K |
|
|
ALR
92
DELISTED
Alere Inc
ALR
| $149K | 0.02% |
4,127
-303
| -7% | -$10.1K |
|
|
ESRX
93
DELISTED
Express Scripts Holding Company
ESRX
| $146K | 0.02% |
+2,080
| New | +$136K |
|
|
ALOG
94
DELISTED
Analogic Corp
ALOG
| $146K | 0.02% |
+1,644
| New | +$150K |
|
95
Standard BioTools
LAB
$271M
| $78K | 0.01% |
+2,030
| New | +$59.8K |
|
|
ENDP
96
DELISTED
Endo International plc
ENDP
| $77K | 0.01% |
+1,138
| New | +$64.9K |
|
97
Puma Biotechnology
PBYI
$477M
| $76K | 0.01% |
+735
| New | +$43.1K |
|
|
RAD
98
DELISTED
Rite Aid Corporation
RAD
| $76K | 0.01% |
+746
| New | +$79.3K |
|
|
AFFX
99
DELISTED
Affymetrix Inc
AFFX
| $73K | 0.01% |
+8,538
| New | +$65.5K |
|
100
Geron
GERN
$842M
| $22K | ﹤0.01% |
+4,956
| New | +$21.3K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Perceptive Advisors held 156 positions worth $833M, down 32% from $1.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Perceptive Advisors withdrew a net $240M in Q4 2013, closing 47 positions and reducing 27 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $69.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in MacroGenics worth $19.7M.
- Perceptive Advisors's largest Q4 2013 buy was MacroGenics: 717,705 shares worth $19.7M.
- Perceptive Advisors added most to Vertex Pharmaceuticals in Q4 2013, an estimated $25M increase.
- Perceptive Advisors's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $144M.
- Perceptive Advisors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $69.5M.
- Perceptive Advisors's ten largest holdings make up 57% of its $833M portfolio in Q4 2013.
- Perceptive Advisors opened 48 new positions and closed 47 in Q4 2013.
- Perceptive Advisors's portfolio value fell 32% quarter-over-quarter to $833M.
Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.